Ginkgo Bioworks grants 25,000 RSUs to director

Ginkgo Bioworks Holdings, Inc. reported that director Ross Fubini received a grant of 25,000 Restricted Stock Units on June 11, 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Ginkgo Bioworks Holdings, Inc. reported that director Ross Fubini received a grant of 25,000 Restricted Stock Units on June 11, 2026. Each RSU represents a contingent right to one share of Class A common stock, with no cash exercise price.

The RSUs vest on the earlier of June 11, 2027 or the day immediately before the next annual meeting after the grant date, subject to Fubini continuing to serve as a non-employee director through the vesting date. Following this award, his directly held RSUs from this grant total 25,000 units.

Insider Trade Summary

Grant/Award: 25,000 shares

Grant/Award 1 txn

Insider Fubini Ross

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	25,000	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 25,000 contracts (Direct)

Footnotes (2)

F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2. In accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Program, which became effective on June 11, 2026, the RSUs shall vest on the earlier of June 11, 2027 or the day immediately prior to the date of the next Annual Meeting occurring after the date of grant, in either case, subject to the Reporting Person continuing in service as a Non-Employee Director through such vesting date.

Key Figures

RSUs granted: 25,000 units Exercise price: $0.00 per RSU Underlying shares: 25,000 shares +2 more

5 metrics

RSUs granted 25,000 units Grant to director Ross Fubini on June 11, 2026

Exercise price $0.00 per RSU Restricted Stock Units have no cash exercise price

Underlying shares 25,000 shares Each RSU converts into one share of Class A common stock

Vesting date latest June 11, 2027 Vests on this date or earlier if before next annual meeting

Holdings after grant 25,000 RSUs Total RSUs from this award following the transaction

Key Terms

Restricted Stock Units, Class A Common Stock, Non-Employee Director Compensation Program, vest

4 terms

Restricted Stock Units financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Class A Common Stock financial

"receive one share of the Issuer's Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

Non-Employee Director Compensation Program financial

"Issuer's Amended and Restated Non-Employee Director Compensation Program"

vest financial

"the RSUs shall vest on the earlier of June 11, 2027 or the day immediately prior"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Ginkgo Bioworks (DNA) disclose for Ross Fubini?

Ginkgo Bioworks disclosed that director Ross Fubini received a grant of 25,000 Restricted Stock Units on June 11, 2026. These units are part of the company’s non-employee director compensation and convert into Class A common shares when they vest, subject to service conditions.

How many RSUs did Ross Fubini receive from Ginkgo Bioworks (DNA)?

Ross Fubini received 25,000 Restricted Stock Units from Ginkgo Bioworks. Each RSU represents a contingent right to one share of Class A common stock, providing equity-based compensation instead of cash, subject to vesting conditions tied to his continued board service.

When do Ross Fubini’s Ginkgo Bioworks (DNA) RSUs vest?

The RSUs vest on the earlier of June 11, 2027 or the day immediately before the next annual meeting after the grant date. Vesting is contingent on Fubini continuing to serve as a non-employee director through that vesting date under the company’s compensation program.

What does each Ginkgo Bioworks (DNA) RSU granted to Ross Fubini represent?

Each Restricted Stock Unit granted to Ross Fubini represents a contingent right to receive one share of Ginkgo Bioworks’ Class A common stock. No exercise price is required; shares are delivered if and when the RSUs vest under the specified service-based conditions.

Is Ross Fubini’s RSU grant at Ginkgo Bioworks (DNA) a purchase or a compensation award?

The 25,000 RSUs granted to Ross Fubini are a compensation award, not an open-market purchase. They were issued under Ginkgo Bioworks’ Amended and Restated Non-Employee Director Compensation Program, providing equity incentives instead of cash, subject to time-based vesting requirements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/15/2026 - 05:04 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fubini Ross

(Last)

(First)

(Middle)

C/O GINKGO BIOWORKS HOLDINGS, INC.

27 DRYDOCK AVENUE

(Street)

BOSTON

MASSACHUSETTS

02210

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ginkgo Bioworks Holdings, Inc. [ DNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	06/11/2026		A		25,000		⁽²⁾	⁽²⁾	Class A Common Stock	25,000	⁽¹⁾	25,000	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

2. In accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Program, which became effective on June 11, 2026, the RSUs shall vest on the earlier of June 11, 2027 or the day immediately prior to the date of the next Annual Meeting occurring after the date of grant, in either case, subject to the Reporting Person continuing in service as a Non-Employee Director through such vesting date.

Remarks:

	/s/ Karen Tepichin, Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR